视频中的韦东奕体格非常消瘦，看不到肌肉；还不到35岁的年纪，上排牙齿已缺失一半，看起来像个小老头。 "弟弟从小就不吃荤菜，但会保证鸡蛋、牛奶等蛋白质的每日摄入，亲友也关心、督促他健身并注重身体健康。"在北大数学科学学院研究员韦东奕亮相社交 媒体的视频发布后，韦东奕的堂姐这样回应外界关注。 在高考前夕，因数学方面的造诣被网友封为"韦神"的韦东奕首次开设了社交媒体账号。截至6月8日早晨，账号粉丝量已突破2100万。 研究者建议，优化饮食结构，适度摄入高质量动物性食品，提高植物性食物的质量。 原央视主持人赵普已于6月7日公开发声，呼吁学校关心并干预韦东奕的健康状况。他认为，韦东奕需要的不是围观和膜拜，而是迫切需要对他身体健康状况 的关心和帮助，韦东奕的家人有责任更好地照顾他，北大也有道义上的义务关心他支持他。 除了均衡的营养摄入之外，运动也是保持健康体魄的关键。国家传染病医学中心主任张文宏教授在近期接受媒体采访时称："人在60岁之前为生活、为工 作、为家人而活；60岁退休后可以说是一个全新的起点，会迎来第二次生命状态！" 对此，韦东奕的堂姐在社交媒体上回应网友称，堂弟患牙周炎并曾多次接受治疗，最近还会带他去医院检查 ...

Financial Data and Key Metrics Changes - In Q1 2025, the company reported revenues of $30,500,000, representing a 38% year-over-year increase [8][18] - Net income for the quarter was $5,100,000, compared to a net loss of $500,000 in Q1 2024 [21] - Cash generated from operations was $7,900,000, a significant increase from $300,000 in the same period last year [22] - The company ended the quarter with $55,600,000 in cash and no debt, maintaining strong liquidity [21] Business Line Data and Key Metrics Changes - E-commerce sales grew by 31% year-over-year, contributing significantly to revenue growth [9][18] - The food grade and pharmaceutical grade Niagen ingredient business saw a 95% increase, reaching $8,000,000 [9][18] - Gross margin improved to 63.4%, up from 60.7% a year ago, driven by a favorable product mix and cost savings [18] Market Data and Key Metrics Changes - The demand for NAD-boosting products is surging, with increasing consumer awareness of Niagen as a trusted solution [12][14] - The company aims to expand its presence in clinics, targeting 1,000 clinics by the end of 2025, with a potential addressable market of 2,000 to 3,000 clinics [42] Company Strategy and Development Direction - The company is focused on reinforcing Niagen as the leading NAD-boosting solution, aligning its brand with its mission of promoting healthy aging [15][16] - The pharmaceutical application of nicotinamide riboside (NR) is a key strategic initiative, with ongoing studies and FDA dialogues [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustained momentum across e-commerce and ingredient businesses, raising the full-year growth outlook to 20% to 25% [22][23] - The company is committed to operational discipline and efficiency, with a focus on long-term profitability [26] Other Important Information - The company announced a new composition of matter patent granted in March, broadening its patent portfolio [11] - Management highlighted the importance of maintaining integrity and scientific rigor in the NAD supplement market [13][14] Q&A Session Summary Question: What are the emerging tailwinds for NIAGEN IV product adoption? - Management noted significant interest from clinics and physicians, with 600 clinics currently offering NIAGEN IV and expectations for increased sales [28][32] Question: Are there new promotional strategies for e-commerce? - Management indicated a focus on profitability and efficiency, with plans to increase presence on platforms like TikTok and engage with influencers [35][37] Question: What is the potential market for NIAGEN plus? - Management aims to onboard 1,000 clinics by year-end, with a larger addressable market identified [42] Question: What is the status of the injectable NIAGEN plus? - Management confirmed that an at-home version is in development, expected to be available by Q4 2025 [72][73] Question: What is the status of the FDA discussions regarding ataxia telangiectasia? - Active discussions are ongoing with the FDA, with a pre-IND submission made and feedback received [90][91]